NCT05077709Phase 2Completed

IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC

Study sponsor: IO Biotech

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2025-11-30Actual
Enrollment · participants63Actual
Source updated2026-04-08Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: ORR or PFS. After: Measure: ORR.

Primary completion date changed

Before: 4 Jan 2024. After: 30 Nov 2025.

Recruitment status changed

Before: Active not recruiting. After: Completed.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview